Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | CASR | P41180 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | KDM5A | P29375 | 2/20 | 0.33 |
| ▸ | PHF8 | Q9UPP1 | 2/20 | 0.33 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.33 |
| ▸ | KDM4A | O75164 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6737845 | 0.93 | SIGMAR1 (0.46) | PKMSIGMAR1EPHX1CASRALDH1A1 | |
| SCHEMBL6734367 | 0.83 | PKM (0.37) | PKMSIGMAR1EPHX1L3MBTL1CNR1 | |
| SCHEMBL6739579 | 0.82 | SIGMAR1 (0.36) | SIGMAR1EPHX1L3MBTL1CASRALDH1A1 | |
| SCHEMBL7220238 | 0.80 | CA12 (0.40) | SIGMAR1KMT2AALDH1A1 | |
| SCHEMBL7213907 | 0.80 | CA12 (0.40) | SIGMAR1KMT2AALDH1A1 | |
| SCHEMBL27457772 | 0.80 | CA12 (0.40) | SIGMAR1KMT2AALDH1A1 | |
| SCHEMBL7213998 | 0.80 | SIGMAR1 (0.46) | SIGMAR1CNR1ALDH1A1 | |
| SCHEMBL7220288 | 0.80 | ALDH1A1 (0.34) | SIGMAR1ALDH1A1 | |
| SCHEMBL7214016 | 0.79 | ACKR3 (0.40) | SIGMAR1EPHX1ALDH1A1 | |
| SCHEMBL7214022 | 0.79 | ACKR3 (0.40) | SIGMAR1EPHX1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1188394-C | N-substituted-N' -substituted urea derivatives and pharmaceutical compositions containing the same | SANTEN PHARMACEUTICAL CO LTD (JP) | 2005-02-09 | — | — | CN | disclosed |
| US-6683200-B2 | N-SUBSTITUTED-N'-SUBSTITUTED UREA DERIVATIVE IS USED AS A TUMOR NECROSIS FACTOR-ALPHA PRODUCTION INHIBITORY AGENT AND A THERAPEUTICAL AGENT FOR AUTOIMMUNE DISEASES | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2004-01-27 | — | — | US | disclosed |
| US-20020068763-A1 | N-substituted-N'-substituted urea derivatives and pharmaceutical compositions containing the derivatives | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2002-06-06 | — | — | US | disclosed |
| CN-1348443-A | N-substituted-N' -substituted urea derivatives and pharmaceutical compositions containing the same | SANTEN PHARMACEUTICAL CO LTD (JP) | 2002-05-08 | — | — | CN | disclosed |
| EP-1172358-A1 | N-SUBSTITUTED-N'-SUBSTITUTED UREA DERIVATIVE AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2002-01-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020068763-A1 | N-substituted-N'-substituted urea derivatives and pharmaceutical compositions containing the derivatives | TNF, NFKBIA, UMPS | PKM 4021/4885SIGMAR1 551/4885EPHX1 2802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.